Introduction What Can We Offer? Workflow Published Data Why Choose Us? Applications FAQs Featured Services Featured Products
Creative Biolabs provides industry-leading bivalent aptamer development services, transforming standard monovalent sequences into high-avidity constructs. We help clients overcome the limitations of weak target binding and rapid off-rates, delivering precision-engineered tools that unlock superior therapeutic and diagnostic performance across complex biological systems.
Contact our team to get an inquiry now!
Introduction of Bivalent Aptamers
Bivalent aptamers are sophisticated molecular constructs comprising two binding domains, either identical (homo-bivalent) or distinct (hetero-bivalent), tethered by a specialized linker. Unlike monomers, these constructs utilize the "avidity effect," where the simultaneous engagement of two epitopes exponentially increases the functional affinity. Recent research highlights that bivalency can reduce dissociation constants (Kd) by up to three orders of magnitude, effectively "locking" the aptamer onto its target. This structural evolution is particularly transformative for targets with low density or those requiring receptor dimerization to trigger biological signaling. Through the optimization of spatial orientation and the flexibility of these dimers, these constructs can be engineered to outperform traditional monoclonal antibodies in stability, cost, and tissue penetration.
Fig.1 Schematics of bivalent aptamers.1
What Can We Offer?
We offer a comprehensive, end-to-end service for the design and synthesis of bivalent aptamers, providing clients with customized solutions that maximize binding strength and biological activity. We also offer aptamer conjugate development services, such as aptamer-antibody conjugates, aptamer-drug conjugates, aptamer-cholesterol conjugates, aptamer-nanoparticle conjugates, and aptamer-based biosensors.
Our Specialized Services:
Target-Specific Geometry Design
We evaluate your target's structural data to determine the optimal bivalent configuration. Whether you require a homo-bivalent construct for receptor clustering or a bispecific hetero-bivalent construct to bridge two different antigens, our team designs the architecture to suit the specific biological mechanism.
Proprietary Linker Optimization
The linker is the "heart" of a bivalent aptamer. We offer a library of chemical spacers, including PEGylated chains, rigid double-stranded DNA segments, and flexible carbon-chain linkers. Our systematic screening identifies the exact length and rigidity required to span the distance between epitopes without inducing steric hindrance.
Affinity and Avidity Characterization
We don't just build; we verify. Our laboratory utilizes Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI) to provide a comparative analysis between your starting monomer and the new bivalent construct, quantifying the exact fold-improvement in koff and overall Kd.
Stability and Nuclease Resistance Profiling
Every bivalent construct undergoes tournament testing in human serum and physiological buffers. We incorporate site-specific chemical modifications (e.g., 2'-F, 2'-OMe, or inverted bases) to ensure your lead candidate survives the proteolytic environment of the human body.
Workflow
01
Initial Consultation & Feasibility: You provide the sequence of your existing monomer(s) and target protein details. We perform a thermodynamic assessment to estimate the potential avidity gain.
02
In Silico Modeling: Our team uses molecular dynamics to simulate various linker lengths and attachment points (3' or 5'), predicting the most stable configurations.
03
Synthesis & Assembly: We synthesize the individual aptamers and chemically conjugate them using high-efficiency click chemistry or phosphoramidite synthesis.
04
Purification & QC: Constructs are purified via HPLC/PAGE and verified through Mass Spectrometry to ensure 100% sequence and linkage integrity.
05
Performance Validation: We perform head-to-head binding assays against the monomer.
06
Final Delivery: You receive the purified bivalent construct, a comprehensive characterization report, and the optimized synthesis protocol.
Published Data
Fig.2 Construction and characterization of the BAD.2
This study showcased the efficacy of bivalent engineering for treating Esophageal Squamous Cell Carcinoma (ESCC). Researchers utilized the C2 aptamer, which specifically recognizes ESCC cells, and engineered a bivalent aptamer-DNA carrier (BAD). By tethering two C2 aptamers through a structural DNA scaffold, the team achieved a significant increase in binding affinity compared to the monovalent form. When utilized as a delivery vehicle for a cytotoxic therapeutic agent, the bivalent construct demonstrated enhanced target-specific killing of ESCC cells both in vitro and in vivo. The BAD conjugate effectively improved the therapeutic index, showing higher accumulation in tumor tissues and reduced systemic toxicity compared to the free drug. This study validates the use of bivalent aptamer scaffolds as high-precision tools for overcoming the limitations of standard monovalent ligands in oncology applications.
Why Choose Us?
-
Proprietary Linker Libraries: We possess a unique catalog of "smart linkers" that adjust to target topography.
-
High-Throughput Verification: We can test dozens of bivalent iterations simultaneously to find the "sweet spot" faster.
-
Custom Chemical Modifications: We offer the widest range of protective chemistries to ensure in vivo longevity.
-
Seamless Scale-up: Our synthesis platform is designed to transition from milligram pilot studies to gram-scale production.
-
Deep Biological Context: We don't just provide chemicals; we provide biological solutions tailored to your specific disease model.
Applications
-
Receptor Tyrosine Kinase (RTK) Activation: Homo-bivalent aptamers successfully mimic natural ligands to induce dimerization and activate receptors like TrkB or VEGFR, offering a robust non-immunogenic path for regenerative medicine and targeted tissue repair within complex biological environments.
-
Immune Cell Recruitment: Hetero-bivalent (bispecific) constructs simultaneously engage tumor antigens and T-cell markers such as CD3, effectively creating an aptamer-based bispecific antibody platform to drive targeted cytotoxicity against resilient malignancies.
-
Ultra-Sensitive Diagnostics: Within lateral flow or ELISA-based platforms, bivalent aptamers achieve significantly lower limits of detection (LOD) due to near-irreversible binding to capture surfaces, enhancing diagnostic reliability for early-stage disease detection and monitoring.
-
Targeted Delivery of Toxic Payloads: The utilization of one binding arm for high-affinity cell-surface anchoring and the second for stimulating rapid internalization enables bivalent scaffolds to maximize the intracellular delivery of siRNAs and chemotherapeutics.
-
Structural Biology and Proximity Assays: These constructs serve as invaluable probes for studying protein-protein interactions by forcing physical proximity between distinct molecular targets, facilitating the exploration of complex signaling networks in live cellular environments.
-
Neutralization of Multimeric Targets: Enhanced avidity allows for the effective neutralization of viral particles or bacterial toxins that present repeated surface epitopes, providing a strategic advantage over monovalent neutralizing agents in infectious disease control.
FAQs
Q: What is the primary difference between bivalent affinity and monovalent affinity?
A: Monovalent affinity refers to the strength of a single interaction, whereas bivalent affinity (avidity) accounts for the synergistic effect of two simultaneous interactions, which drastically reduces the likelihood of the molecule detaching from the target.
Q: Can you develop a bivalent aptamer if I only have one known sequence?
A: Absolutely, we can create a "homo-bivalent" construct by linking two copies of your existing sequence, which is often sufficient to achieve a massive increase in binding residence time.
Q: How do you determine the correct linker length for a specific protein?
A: Our process begins with computational modeling of the target's surface; we then synthesize a "Linker-Scan" series with varying lengths to experimentally identify which one allows for optimal dual-epitope engagement.
Q: Will bivalency affect the solubility of my aptamer?
A: While doubling the size increases the molecular weight, nucleic acids are inherently hydrophilic; we further optimize solubility by selecting linkers like PEG that enhance the pharmacokinetic profile without causing aggregation.
Q: Is it possible to link two different types of aptamers, such as a DNA and an RNA aptamer?
A: Yes, our chemical conjugation techniques allow for the hybrid assembly of different nucleic acid chemistries, enabling "hetero-bivalent" designs that can target two distinct molecular markers.
Q: Can these constructs be used for imaging?
A: Definitely, as we can easily conjugate fluorescent dyes or radiolabels to the linker region, allowing the bivalent aptamer to serve as a highly specific, high-contrast imaging agent.
Q: What happens if the two binding sites on the protein are too far apart?
A: If the epitopes are beyond a certain distance, we utilize "extended" or "rigid" linkers to bridge the gap, or we may suggest a hetero-bivalent approach targeting two different proteins within a complex.
Creative Biolabs combines decades of biological expertise with precision chemical engineering to deliver superior bivalent aptamers. We invite you to leverage our advanced platform to enhance your lead candidates. Contact our team to transform your monovalent binders into high-performance therapeutics.
Featured Services
Featured Products
References
-
Kim, Minhee, et al. "Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents." Molecules 23.4 (2018): 830. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3390/molecules23040830
-
Zhang, Tianlu, et al. "Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells." International Journal of Molecular Sciences 25.14 (2024): 7959. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms25147959
Questions & Answer
A: We offer custom bivalent aptamer development services tailored to specific client requirements. We provide expertise and services in design, synthesis, characterization, and optimization of bivalent aptamers.
A: Developing bivalent aptamers involves challenges such as linker optimization, maintaining individual aptamer functionality, and achieving the desired binding properties. Creative Biolabs has expertise in addressing these challenges during the development process.
A: Bivalent aptamers are typically developed on a custom basis to suit specific research or therapeutic needs. Creative Biolabs offers custom bivalent aptamer development services, but the availability of specific aptamers may vary.
For Research Use Only.
Related Sections:
